Berto Tejera-Hernandez

Berto Tejera-Hernandez has a varied work experience in the scientific field. From 2022 to present, they have been a Scientist I at ReCode Therapeutics. From 2019 to 2022, they were a Postdoctoral Research Fellow at the University of Michigan, where they elucidated the mechanism of antiviral PKR protein degradation in mouse adenovirus infection, purified plasmids and transfected them in several human and mouse cell lines, and performed DNA and RNA purification from infected cells and analyzed them by qPCR and RT-qPCR respectively. From 2016 to 2019, they were an Associate Researcher at Codigo46 (a human genotyping company), where they handled human saliva and buccal swab samples, was familiar with data privacy, optimized different DNA extraction methods from human saliva and buccal swabs samples, and prepared research reports for internal stakeholders.

Berto Tejera-Hernandez obtained a Doctor of Philosophy - PhD in Virology from the Autonomous University of the State of Morelos, UAEM in Mexico in 2019. Prior to this, they obtained a Bachelor's degree in Microbiology and Virology from the School of Biology, University of Havana in 2008.